Aptevo Therapeutics Inc APVO 深 滬
交易中 12-17 10:25:59 美东时间
1.07
-0.030
-2.73%
華盛通- 最 高1.10
- 今 開1.10
- 成交量 13.30万股
- 最 低 1.06
- 昨 收 1.10
- 總市值 1803.00万
- 52周最高 109.80
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 1.00
- 委 比 51.57%
- 總股本 1685.05万
- 歷史最高 3778913.60
- 量 比 0.55
- 振 幅 3.64%
- 歷史最低 1.06
- 每 手 1
- 風險率 33.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
12-11 23:17
Aptevo Therapeutics Announces Promising RAINIER Trial Results
Aptevo Therapeutics ( ($APVO) ) just unveiled an announcement. On December 9, 2...
12-10 06:48
Aptevo Therapeutics Presents Preliminary Results From Ongoing Phase 1b/2 RAINIER Study Evaluating Mipletamig In Combination With AZA/VEN For Newly Diagnosed AML Patients, At ASH Annual Meeting
100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of
12-09 21:12
Aptevo Therapeutics Q3 EPS $(2.23) Misses $(2.09) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(2.23) per share which missed the analyst consensus estimate of $(2.09) by 6.7 percent. This is a 99.38 percent increase over losses of $(357.86) per share
11-06 21:37
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket
Shares of Telomir Pharmaceuticals Inc (NASDAQ:TELO) rose sharply in pre-market ...
10-07 17:28
Market-Moving News for September 18th
INTC: 34% | Nvidia And Intel To Jointly Develop AI Infrastructure And Personal Computing Products, Nvidia To Invest $5B In Intel's Stock At $23.28 Per Share NVO: 7% | Novo Nordisk Announced Ozempic Reduces
09-18 19:21
Aptevo Announces 100% Remission in AML Trial
Aptevo Therapeutics ( ($APVO) ) just unveiled an announcement. On September 16,...
09-17 05:30
Aptevo's Mipletamig Achieves 100% Remission With Favorable Safety In Phase 1b/2 AML Trial; Cohort 4 Now Open For Enrollment
No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerabilityTrial progressing efficiently, Cohort 4 open for enrollmentSEATTLE, WA
09-16 20:33
Aptevo Expands Anti-Cancer Pipeline With Patents For APVO452, APVO451; Acute Myeloid Leukemia Candidate Mipletamig Shows Strong Clinical Validation
New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive
09-04 20:50
Aptevo Unveils APVO442 Precision CD3 Bispecific For Prostate Cancer, Advancing Solid Tumor Strategy With CRIS-7 Platform
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3
08-13 20:14
